Will the Bengals rookie QB throw an interception vs. the Steelers?
Will the Bengals rookie QB throw an interception vs. the Steelers?
(Bloomberg) -- The divergence of manufacturing data in Southeast-Asian nations -- Indonesia, Thailand, Malaysian and the Philippines -- may prove to be a harbinger for their bond-market performances heading into 2021.Purchasing managers indexes for Indonesia and Thailand published this week were both above the 50 threshold, indicating expansion. For Malaysia and the Philippines the figures remained stubbornly below that level. For Indonesia, the gauge has risen for six of the past seven months, while the Thai index has signaled growth for two straight months for the first time this year.The robust manufacturing numbers chime with the recent performance of debt from the two nations. Indonesian bonds have returned 10% this quarter to dollar-based investors, leading emerging Asia, while Thailand is second at 5%.While rising PMIs don’t automatically translate into higher bond prices and a stronger currency, they are an important contributor to the overall narrative. In adding another sign of recovery from the coronavirus pandemic, they have helped lure $2.5 billion of inflows into Indonesian sovereign bonds this quarter, the most in more than a year, and $1 billion into Thai debt in the same period.Worse PictureThe picture is less promising in Malaysia and the Philippines. Malaysia’s PMI stayed below 50 for a fourth month in November, while the Philippines showed a contraction for a second straight period. Bond performance has also been muted in the two countries, with Malaysian and Philippine debt both returning just 1.6% this quarter, the worst performers in emerging Asia.The sub-par manufacturing figures appear linked to social-distancing measures, which have curtailed both production and consumption. Malaysia’s major economic centers, the capital Kuala Lumpur and the state of Selangor, are both under movement restrictions which are set to expire on Dec. 6, although a surge in infections poses the risk they will be extended.Malaysia has the highest lockdown score in the region, according to indexes compiled by Goldman Sachs Group Inc., which measure the severity of the restrictions and their impact on mobility. The Philippines isn’t far behind at 45.2, whereas Indonesia has a level of 21.9, and Thailand just 10.2.The restrictions are having an impact on economic growth. Malaysia last month downgraded its forecast for this year’s gross domestic product to a contraction of 4.5% to 5.5%, citing the lockdown measures. The Philippine central bank unexpectedly cut interest rates on Nov. 19 following a bigger-than-forecast decline in GDP. A decision to ease borrowing costs again will be complicated by rising inflation after price growth accelerated to a 20-month high in November.The latest batch of PMI data don’t tell the whole story about the relative performance of the four main Southeast Asian economies, but they do help shine a light on their relative underlying strength. The divergence at present appears to correlate with bond performance, and may indicate which debt markets are set to be the strongest at the start of 2021.What to WatchThe Philippines will release October trade numbers on Thursday, after exports rose in the previous month for the first time since FebruaryMalaysia will publish industrial production figures on FridayNote: Marcus Wong is an EM macro strategist who writes for Bloomberg. The observations he makes are his own and not intended as investment advice.(Updates with latest Philippine inflation data in eighth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Yields on short- to mid-dated Japanese government bonds inched lower on Friday as current dire conditions of the pandemic and concerns about COVID-19 vaccine supply clouded risk sentiment. Benchmark 10-year JGB futures rose 0.01 point to 151.98, with a trading volume of 18,047 lots, while the 10-year JGB yield fell half-a-basis point to 0.015%. At the shorter end of the curve, the two-year JGB yield and the five-year yield lost half-a -basis point to minus 0.135% and minus 0.110%, respectively.
Investors worried about whether a looming government shutdown could slow U.S. stocks' recent surge can take comfort in history: markets have tended to shrug off shutdowns despite their potentially nasty economic impact. Since 1984, the S&P 500 has averaged a 1.3% gain during government shutdowns, having edged lower in only two out of the last 10 instances. The most recent shutdown, which lasted for five weeks, shaved 0.1% and 0.2% from real U.S. gross domestic product in the fourth quarter of 2018 and the first quarter of 2019, respectively, according to the Congressional Budget Office.
U.S. lawmakers unveiled the final version of a massive annual defense policy bill on Thursday that defies President Donald Trump's plans to withdraw troops from Germany and keep the names of Confederate generals on military bases, setting the stage for a veto fight in the last weeks before he leaves office. The $740 billion, 4500-page National Defense Authorization Act, or NDAA, is the result of months of negotiations between Republicans and Democrats in the Senate and House of Representatives. Among other things, the bill expresses support for the continued presence of U.S. forces in Germany and limits the ability of the Department of Defense to reduce the number of active-duty service members there below 34,500 without an assessment of its impact.
(Bloomberg) -- Shares of the media company founded by Hong Kong government critic Jimmy Lai surged as much as 107% as they resumed trading Friday, following his detention on charges related to an earlier arrest under the China-drafted national security law.It was briefly the biggest gain for Next Digital Ltd. since the days following Lai’s August arrest. Back then, the stock surged 1,100% in two sessions to a seven-year high before wiping out those gains.The advance pared to 30% as of 1:53 p.m. in Hong Kong, the stock having resumed trading after being halted on Thursday after Lai’s arrest. “It’s purely speculative,” said Kenny Wen, an analyst at Everbright Sun Hung Kai Co. Ltd., of Friday’s gains. “The stock is too volatile and the risk of reversion is very high, as we saw in August. Things can turn around very quickly and investors will lose out if they can’t pull out in time.”Hong Kong police in October arrested more than a dozen people in connection with the summer surge on suspicion of the use of illegal funds and conspiracy to defraud. Police said one of the people had links to organized crime, and six were unemployed.Lai, 73, was this week denied bail on the new charges related to the August arrest, which could potentially keep him behind bars for months as he fights the allegations.The publisher and his fellow executives were charged with violating the lease terms of the office park housing Next Digital’s headquarters by basing a family office there to manage his personal finances. He wasn’t immediately charged with potentially more serious allegations of foreign collusion under the security law, which in August prompted his arrest and a dramatic raid of the newsroom of Next Media’s Apple Daily newspaper.Hong Kong Tycoon Jimmy Lai Denied Bail in Ongoing Crack Down (1)China’s crackdown on Hong Kong dissent has prompted international condemnation, and the U.S. has hit Chief Executive Carrie Lam and several other officials responsible for the city with sanctions. Lam said she was collecting “piles of cash” at home because the financial measures were barring her from basic banking services.Hong Kong authorities have moved quickly to employ the sweeping legislation, which carries sentences as long as life in prison, since it was imposed by China without local debate in June. The police unit tasked with enforcing the measure has so far arrested 32 people, most for allegations related to slogans, banners or Internet posts deemed to be secessionist or seditious.(Updates stock price in the third paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Super Formula points leader Ryo Hirakawa set the pace in practice for this weekend's Suzuka double-header with a new lap record around the Japanese Grand Prix venue.
The Automotive Software Market will grow by $ 10.70 bn during 2020-2024
A Sydney horror film fan with a host of mental disorders suffered from a loss of control when committing a violent homicide, two psychiatrists have told a jury.
Image source: The Motley Fool. Zuora, Inc. (NYSE: ZUO)Q3 2021 Earnings CallDec 03, 2020, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood afternoon, and welcome to Zuora's third-quarter fiscal 2021 earnings conference call.
Good afternoon, and thank you for joining us today for our discussion of Ulta Beauty's results for the third quarter of fiscal 2020. Hosting today's call are Mary Dillon, chief executive officer; and Scott Settersten, chief financial officer.
AstraZeneca and Oxford University have given conflicting accounts of how they came upon the most effective dosing pattern for their COVID-19 vaccine, a rare instance of public dissension between major institutions collaborating on a pivotal project. The half-dose pattern was found to be 90% effective, versus the 62% success rate of the two-full-dose main study, based on interim data. AstraZeneca's research chief told Reuters 10 days ago, when interim trial data was released, the half-dose was given inadvertently as a first shot to some trial participants, and emerged as a stroke of fortune - "serendipity" - that scientists expertly harnessed.
UBS Group AG said on Friday it appointed Chief Operating Officer and President EMEA Sabine Keller-Busse as president of UBS Switzerland, while Iqbal Khan, co-president of global wealth management, will succeed Keller-Busse as president EMEA, in addition to his current role. Keller-Busse, who joined UBS in 2010 and was named Group COO in 2018, succeeds Axel P. Lehmann who has decided to step down from his current roles as president personal & corporate banking and president UBS Switzerland at the end of January 2021, and will leave the bank after a transition phase at the end of July, UBS said in a statement.
To better serve the North American market WindSim and Cognite product offerings are expanded to include transmission line performance monitoring and evaluation of enhanced current carrying capacity targeted at wind plant integrationAUSTIN, Texas, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Cognite, a global industrial AI software-as-a-service (SaaS) company supporting the full-scale digital transformation of heavy-asset industries around the world, announces a new collaboration with WindSim, a leading provider and pioneer of Computational Fluid Dynamics (CFD) based Wind Farm Design Tools (WFDT) utilized for the design of wind farms both onshore and offshore. This partnership will maximize new and existing asset performance, increase energy efficiency, and reduce transmission bottlenecks and costs in the power and utilities industry. This offering is a direct response to the need for advanced software that enables power & utility customers to better adapt their operations to dynamic industry change.WindSim’s simulation technology makes industrial data valuable to engineering and operations teams so they can plan more effective offshore wind farms and maximize the efficiency of existing transmission and distribution infrastructure. This level of advanced analytics is supported by Cognite’s data operations and contextualization platform called Cognite Data Fusion (CDF), which contextualizes industrial data and makes it actionable. Combined, this offering puts simulation analysis in context with real-world data and operational decisions.“The application of CFD technology and other advanced methods in the wind energy industry is an important part of the decisioning process for greenfield and brownfield projects,” said Donna Rennemo, CEO of WindSim. “With Cognite Data Fusion, WindSim’s unique solution can leverage high-fidelity data and paint a clearer picture of the potential decision outcomes. Making data do more so that it is available, processed, and simulated well, helps wind farm owners and transmission owners and operators optimize operations, reduce costs and reduce investment risks.”Trygve Ronningen, Chief Operating Officer of Cognite North America adds, “This collaboration with WindSim deploys an important layer of value and clarity on top of inherently messy industrial data. By enabling WindSim to leverage prepared data and scale with less effort, organizations can more effectively move from proofs of concept to productized, high-ROI deployment.”Webinar Alert: Register here to attend an upcoming webinar and learn more from Cognite and WindSim about how to enable flexible, efficient transmission operations on December 16th, 2020 3pm - 4pm (CST) / 10pm - 11pm (CET)About WindSim WindSim develops and delivers advanced software solutions and consulting services that help worldwide wind energy industry leaders design more profitable wind farms. WindSim, the company's flagship product, is a world-class software solution based on Computational Fluid Dynamics (CFD) that combines advanced numeric processing with compelling 3D visualization in a user-friendly interface. Founded in 1993, WindSim is privately-held and venture-backed.About CogniteCognite is a global industrial software-as-a-service (SaaS) company supporting the full-scale digital data driven transformation of heavy-asset industries around the world. Our core product, Cognite Data Fusion (CDF), is an industrial data operations and contextualization platform, putting raw data into real-world industrial context, enabling rapid application & solution creation at scale. CDF powers companies with contextualized OT/IT/ET data to develop solutions that increase safety, sustainability, efficiency, and drive revenue. Visit us at www.cognite.com and follow us on Twitter @CogniteData or at LinkedIn: https://www.linkedin.com/company/cognitedataMedia Contacts: Michelle Holford - Cognite +4748290454 (Norway) +1512 744 3420 (US) firstname.lastname@example.org \------ Donna Rennemo - WindSim Phone: +1 805 216 0785 email@example.com
* Preliminary data from the Phase 1 trial are expected first half 2021 * Additional €3.4 million in non-dilutive funding from SPW-Recherche of the Walloon Region to support advancement of CYAD-211MONT-SAINT-GUIBERT, Belgium, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced dosing of the first patient of the Phase 1 IMMUNICY-1 trial of CYAD-211, the Company’s novel, short hairpin RNA (shRNA)-based anti-B-cell maturation antigen (BCMA) candidate for the treatment of relapsed/refractory multiple myeloma (r/r MM). “Despite the introduction of several new treatment options over the past few years, multiple myeloma remains a devastating disease with a high unmet need for new therapies. We are proud to participate in the IMMUNICY-1 trial which will evaluate CYAD-211 in the treatment of relapsed or refractory multiple myeloma patients,” said professor Dr. Sébastien Anguille, CAR T specialist at the Antwerp University Hospital (UZA), Edegem, Belgium. “Based on the encouraging preclinical data, we believe this new allogeneic CAR T targeting BCMA has the potential to become an important therapy for such a challenging patient population.”Frédéric Lehmann, VP of Clinical Development & Medical Affairs at Celyad Oncology, added, “Dosing the first patient with CYAD-211 marks another major milestone to systematically advance our pipeline of non-gene edited allogeneic CAR T candidates. BCMA is highly expressed in multiple myeloma patients and we hope to see a positive clinical benefit with our approach of targeting BCMA with our first-in-class CAR T which is underpinned by our shRNA technology. Enrollment in the IMMUNICY-1 trial will continue over the coming months and we expect to report proof-of-concept data from the initial dose cohorts of the trial during the first half of 2021.”Financial UpdateThe Company received €3.4 million in non-dilutive funding from the SPW-Recherche of the Walloon Region, which will support the development of CYAD 211. Under the terms of this funding, the Company was awarded non-dilutive funding in the form of recoverable cash advances (‘avances récupérables’). The regional funding is associated with the Company’s specific research and development programs. Under the applicable conditions, the recoverable cash advance is reimbursable over the economic life of the projects. Thirty percent is refundable based on a fixed reimbursement schedule of 20 years, while the balance is refunded under the form of royalties over the same period.The Company confirms its previous guidance that its existing treasury position should be sufficient, based on the current scope of activities, to fund operating expenses and capital expenditure requirements into the third quarter of 2021.About CYAD-211CYAD-211 is an investigational, shRNA-based allogeneic CAR T candidate for the treatment of r/r MM. CYAD-211 is engineered to co-express a BCMA targeting chimeric antigen receptor and a single shRNA, which interferes with the expression of the CD3ζ component of the T cell receptor complex. In July 2020, Celyad Oncology announced FDA clearance of its IND application for CYAD-211.About IMMUNICY-1 Phase 1 TrialThe open-label, dose-escalation trial will evaluate the safety and clinical activity of a single infusion of CYAD-211 following preconditioning chemotherapy cyclophosphamide (300 mg/m²) and fludarabine (30 mg/m²) in patients with relapse or refractory multiple myeloma. The trial will evaluate multiple dose levels of CYAD-211: 3x107, 1x108 and 3x108 cells per infusion. For more information, please visit www.clinicaltrials.gov, study identifier number NCT04613557. About shRNA PlatformCelyad Oncology is focused on the development of its proprietary non-gene edited allogeneic shRNA technology platform. The shRNA platform coupled with the Company’s All-in-One vector approach provides flexibility, versatility, and efficiency to the design of novel, off-the-shelf CAR T candidates through a single step engineering process. Next-generation candidates exploring the breadth and depth of the Celyad Oncology shRNA platform are currently under preclinical development. In 2018, Celyad Oncology signed an exclusive agreement with Horizon Discovery Group for the use of its SMARTvector shRNA technology for the development of allogeneic CAR T therapies.About Celyad OncologyCelyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of CAR T therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.Forward-Looking StatementThis release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include statements regarding: the clinical development of CYAD-211 and timing of expected data from the Phase 1 IMMUNICY-1 trial and the expected use of the non-dilutive funding from the Walloon Region. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risk and uncertainty includes the duration and severity of the COVID-19 pandemic and government measures implemented in response thereto. A further list and description of these risks, uncertainties and other risks can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on March 25, 2020 and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.Investor and Media Contacts:Sara Zelkovic Director Communications & Investor Relations Celyad Oncology firstname.lastname@example.orgDaniel Ferry Managing Director LifeSci Advisors, LLC email@example.comSource: Celyad Oncology SA
Airlines eager to fill premium seats left empty by the coronavirus crisis are making a beeline for the entertainment and energy industries, which still must get its workers to far-off places. Most companies have slashed spending on corporate travel, leaving airlines without a crucial source of revenue. While travel groups expect new COVID-19 vaccines to help revive future business traffic, sectors like sporting events, streaming and content creation are a rare bright spot for airlines in the hard-hit travel sector.
ROTTERDAM, The Netherlands (4 December 2020) – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announced the acquisition of two speciality distribution companies in Mexico, Millikan S.A. de C.V. (“Millikan”) and Banner Química S.A. de C.V. (“Banner Química”). “It has been a very active year for our IMCD Mexico team, and we are pleased to maintain our growth momentum with the acquisitions of Millikan and Banner Química in this important Latin American market,” said Marcus Jordan, Americas President, IMCD. “Both companies perfectly complement our existing operations in Mexico and strengthen our technical and commercial offering in a number of core market segments.”Both based in Mexico City, Millikan and Banner Química collectively generated a revenue of USD 15 million in 2019 and add 60 employees to the IMCD Mexico team. This latest development is preceded by the establishment of IMCD Mexico in April 2020, which serves the pharmaceuticals, food, nutrition, and personal care industries. “Joining IMCD puts our company on the global map and we are delighted to share a mutual desire to offer market differentiation through technical expertise and trend-based solutions for the customers we serve,” said Francisco Camacho, General Director, Millikan. Millikan was established in 1998 and offers technical support and commercial expertise to customers in the food, nutrition, pharmaceuticals, and industrial markets. “I anticipate that IMCD’s reputation for professionalism and market proficiency will create new opportunities for innovation and growth for our loyal customers and principal partners,” said Salvador Ramos, General Director, Banner Química. Banner Química has delivered formulatory solutions for the personal care and home care industries since 2009. The acquisition of Millikan and Banner Química also enhances IMCD’s technical capabilities through the addition of its food and personal care laboratories, further strengthening IMCD’s global network of technical centres.-xxx-Attached, please find the release in pdf format.Attachment * Press Release-IMCD Mexico continues growth momentum with acquisition of Millikan and Banner Quimica
(Bloomberg) -- President-elect Joe Biden said he would ask all Americans to wear a mask to prevent the spread of the coronavirus for the first 100 days of his administration. The U.S. posted another day of record Covid-19 infections and deaths.New York City’s average number of coronavirus cases and its infection rate hit the highest levels since May, while statewide daily infections closed in on 10,000. New Jersey reported record cases. California will impose a new shelter-at-home order if hospitals start running short of intensive-care capacity.In Asia, Osaka raised its virus alert to the highest level after a rise in serious cases put strain on the Japanese prefecture’s medical system. South Korea’s number of newly confirmed cases rose to the highest since early March and its capital Seoul calls for cutting late night activities. Key Developments:Global Tracker: Cases reach 65 million; deaths top 1.5 millionPfizer scaled back vaccine output targets earlier this yearCovid fighters run out of weapons with virus spreading in homesCovid’s Sun-Belt return targets Miami, Phoenix and Las VegasOperation Warp Speed and U.K. vaccine drive leave Europe behindN.Y. developers hire influencers to sell homes during CovidVaccine Tracker: Covid-19 inoculations are about to beginSubscribe to a daily update on the virus from Bloomberg’s Prognosis team here. Click CVIDSeoul Calls for Reducing Late Night Activities (1:43 p.m HK)Seoul strengthens the city’s social distancing measures from Dec. 5, including reducing the frequency of public transportation after 9pm. Its mayor urges citizens to stop late night, outside activities after 9pm for two weeks. This comes as the number of newly confirmed cases in the capital reached a record 295 in the latest tally.Philippines Allows Conventions in Malls, Hotels (11:36 a.m. HK)Philippines has allowed hotels, malls and restaurants to host meetings and conventions after reported coronavirus infections declined in the past days.Economic managers are pushing to further reopen the economy that’s forecast to shrink as much as 9.5% this year. The Philippines has the second-worst outbreak in Southeast Asia, even as daily cases have declined over the past days.South Korea’s Newly Confirmed Cases at Highest since March (8:43 a.m. HK)South Korea reports 629 new coronavirus cases in 24 hours vs. 540 a day earlier, according to data from the Korea Disease Control and Prevention Agency’s website.The number of newly confirmed cases was at the highest since early March and officials are eyeing more steps to curb the virus spread.Japan’s Second-Biggest Region on Highest Alert (7:14 a.m. HK)The Osaka prefectural government raised its virus alert to the highest level after a rise in serious cases put strain on its medical system.Governor Hirofumi Yoshimura, at a news conference late Thursday, urged residents to stay home until Dec. 15. Schools will remain open but bars and restaurants in certain districts are being asked to close early.Osaka reported 386 new cases Thursday; number of patients with serious conditions rose to 136, meaning two-thirds of hospital beds have been occupied, according to Kyodo.Biden Says He’ll Ask All Americans to Wear Masks for 100 Days (7:06 a.m. HK)President-elect Joe Biden said he would ask all Americans to wear a mask to prevent the spread of the coronavirus for the first 100 days of his administration as well as issue a “standing order” requiring face coverings in federal buildings and on all interstate transportation.“Not forever, for 100 days,” he said. “And I think we’ll see a significant reduction” in infections.North Carolina Hits Record Cases, Hospitalizations (7 a.m. HK)North Carolina reported a record 5,637 new infections and the highest number of hospitalizations since the pandemic began. Governor Roy Cooper urged residents to “take personal responsibility” in following the state’s mask order and other health measures but warned of tighter restrictions. “Everything is on the table in weeks to come,” he told reporters, according to the Raleigh News and Observer.Texas’ Caseload Explodes (6:17 p.m. NY)Texas logged its fourth straight day of 10,000-plus new virus cases, the longest such streak since the height of the state’s initial outbreak in July, state health department figures showed.The second-largest U.S. state posted 13,857 new diagnoses, driving the cumulative total to 1.22 million. Virus hospitalizations climbed for a sixth straight day, reaching 9,151, a 54% increase from a month ago, the data showed.Delaware Issues Stay-at-Home Advisory (5:01 p.m. NY)Delaware issued a stay-at-home advisory, halting in-person learning at schools, prohibiting winter sports competitions and requiring people to wear masks indoors if mixing with another household. The order runs from Dec. 14 through Jan. 11.The state already requires masks in public settings -- and the new order does not change the rules for people at work or commuting.Colorado Projects Thousands More Deaths (4:43 p.m. NY)Covid-19 could kill between 2,000 and 4,400 people in Colorado this month, based on official state modeling data released Thursday. “The numbers could go up by as much as several thousand deaths,” said Jon Samet, dean of the Colorado School of Public Health, during an online news conference.It is estimated 1-in-40 of the state’s population of 5.7 million are currently infected, Samet said. “We have a population that is fatigued with doing what it needs to do,” Samet said. “I don’t like to be a grim prognosticator here. But if the curve keeps rising” it’s estimated “we’ll see more hospitalizations, more cases, more deaths,” he said.N.Y. Hospitalizations Most Since May (4:01 p.m. NY)Coronavirus hospitalizations in New York topped 4,000 for the first time since late May, as new cases in the state closed in on 10,000 a day, Governor Andrew Cuomo said Thursday.The state is focusing on increasing the number of hospital beds available as fears of overwhelming the hospital system increase. There currently are about 53,000 hospital beds statewide, 35,000 of which are occupied, Cuomo said.The state can increase to up to 75,000 beds using its “surge and flex” program, he said, adding that about 19,000 coronavirus patients were hospitalized at the peak of the pandemic in March and April.California to Lock Down If ICUs Fall Short of Capacity (3:49 p.m. NY)California, the first state to tell residents to stay home to fight the coronavirus pandemic, may be about to do it again.Governor Gavin Newsom warned Thursday that the state would impose a new shelter-at-home order if hospitals start running short of intensive-care capacity, a dire possibility that could happen in some areas as soon a this week.“The bottom line is if we don’t act now, our hospital system will be overwhelmed,” he said.The order would be imposed in specific regions -- such as the San Francisco Bay Area or Southern California -- rather than statewide. It would take effect once a region’s hospitals had only 15% of their intensive care unit beds available, a threshold none has crossed so far. If imposed, the order would last three weeks.Ramaphosa Reinstates Curbs in South African Hot Spot (1:50 p.m. NY)South African President Cyril Ramaphosa reimposed several curbs aimed at containing the coronavirus pandemic in one of the nation’s biggest municipalities, which is battling a second wave of infections.A 10 p.m. to 4 a.m. curfew will be reinstated in Nelson Mandela Bay in the south of the country, Ramaphosa said in a televised address on Thursday. Alcohol sales be restricted and the consumption of alcoholic beverages in public spaces will be forbidden.The number of new coronavirus cases in South Africa jumped to 4,400 on Wednesday, the highest since mid-August, Ramaphosa said. Of the 800,872 people diagnosed with the disease in the country so far, 92% have recovered, while 21,803 have died.N.J. Reports Most Cases Since Pandemic Began (1:35 p.m. NY)New Jersey reported 4,913 new cases of Covid-19, the most since the state’s first case was disclosed on March 4. The high number partly reflects vastly expanded testing: Like many states early in the pandemic, New Jersey tested only those with virus symptoms. Now the state routinely processes 30,000-plus specimens per day, and last month ran more than 75,000 tests over 24 hours.The positivity rate, 13.68% on Nov. 28, is the highest since May as was the number of patients currently hospitalized, at 3,292. In addition, 64 deaths were reported.Moderna Vaccine May Offer Lasting Protection (11:57 a.m. NY)Moderna Inc.’s Covid-19 vaccine appears to offer potent protection against coronavirus that will last a minimum of three months and potentially much longer, according to a letter from the researchers who conducted the trial published in the New England Journal of Medicine. The number of antibodies produced to fight the infection dropped slowly over time, though they remained elevated and started to plateau three months after volunteers received the second injection.While specific details the immune response needed to confer lasting immunity to the virus are still unclear, the initial findings suggest the vaccine has the potential to provide durable immunity, they said.The vaccine also triggered the production of helper T cells, a critical component of the immune system, 43 days after volunteers received their first shot, though longer studies are needed and are underway, they said.Italy Reports Record Deaths (11:44 a.m. NY)Italy reported a record number of daily coronavirus deaths Thursday, surpassing March’s peak, as the government laid out a plan to restrict movements over the coming holiday season.New fatalities linked to the pandemic hit 993, ahead of 969 on March 27. Some 23,225 new cases were recorded, down 20% from the same day last week. The test positivity rate was stable, at about 10%.The Italian government approved a new plan to stem the spread of the virus over the Christmas and New Year season, banning movements between regions from Dec. 21 to Jan. 6. Movements between different towns will also be halted on Dec. 25, Dec. 26 and Jan. 1.Fauci Says He Will Stay on Under Biden (10:10 a.m. NY)Anthony Fauci, the top infectious-disease expert in the U.S., will continue at the National Institutes of Health under President-elect Joe Biden’s administration, he told CBS in an interview.Fauci also said he’ll take a Covid-19 vaccine in public after it has been approved by the FDA, adding he wished the U.K. had spent more time reviewing the Pfizer vaccine.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Sydney dance company Dirty Feet runs 'The Right Foot' program for people with and without disability.
A Senate inquiry has heard the actions ex-NSW MP Daryl Maguire, accused of abusing his public office, led to three people gaining Australian citizenship.
Skipper Kane Williamson's 251 has powered New Zealand to 7-519 declared at stumps on the second day of the first Test against the West Indies.